Neuronetics (STIM) announced that Humana (HUM) has become the first commercial payer to update its policy in response to the Company’s recent clearance from the U.S. Food and Drug Administration, FDA, for NeuroStar TMS, transcranial magnetic stimulation, as a first-line add-on for adolescents aged 15-21 with MDD, major depressive disorder.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana Inc. Announces CEO Transition and Advisory Role Shifts
- Third Point lists Meta, Amazon among Q1 winners, starts position in Advance Auto
- Humana price target lowered to $353 from $415 at RBC Capital
- Humana price target lowered to $370 from $415 at Oppenheimer
- Humana price target lowered to $360 from $391 at Cantor Fitzgerald